{"version":"1.0","provider_name":"The Medical Xchange","provider_url":"https:\/\/themedicalxchange.com\/en\/","title":"Safety Data for Established and Newer Disease-Modifying Therapies in Multiple Sclerosis: Key Data from ECTRIMS - The Medical Xchange","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"h8M2bDu1RU\"><a href=\"https:\/\/themedicalxchange.com\/en\/2012\/11\/04\/28th-congress-of-the-european-committee-for-treatm\/\">Safety Data for Established and Newer Disease-Modifying Therapies in Multiple Sclerosis:  Key Data from ECTRIMS<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/themedicalxchange.com\/en\/2012\/11\/04\/28th-congress-of-the-european-committee-for-treatm\/embed\/#?secret=h8M2bDu1RU\" width=\"600\" height=\"338\" title=\"&#8220;Safety Data for Established and Newer Disease-Modifying Therapies in Multiple Sclerosis:  Key Data from ECTRIMS&#8221; &#8212; The Medical Xchange\" data-secret=\"h8M2bDu1RU\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script type=\"text\/javascript\">\n\/* <![CDATA[ *\/\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/themedicalxchange.com\/wp-includes\/js\/wp-embed.min.js\n\/* ]]> *\/\n<\/script>\n","thumbnail_url":"https:\/\/themedicalxchange.com\/wp-content\/uploads\/2012\/11\/ECTRIMS_2326_EN_Table_1.PNG","thumbnail_width":960,"thumbnail_height":720,"description":"Lyon - New data confirm the importance of periodically recalculating the risk-to-benefit ratio of disease-modifying therapies (DMTs) for multiple sclerosis (MS). For the newer oral and injectable agents, the ultimate safety will not be fully understood until the risk of late adverse effects from altered immune function or unexpected organ toxicities can be fully quantified over lengthy follow-up. For the established injectable DMTs, data now being collected in populations not well represented in the registration trials, such as adolescents and pregnant women, are providing a broader perspective on where these treatments fit. Safety data relevant to both types of risk calculations were presented at the 2012 ECTRIMS."}